Ampion™ for Inflammation
Ampion™ is an NME being developed as a non-steroidal injection and oral drug for the treatment of diseases involving inflammation. As a mimic of a naturally occurring human molecule, Ampion™ is predicted to have an excellent human safety profile. Ampion™ selectively reduced inflammatory and immune responses in a variety of in vitro and ex vivo investigations that included human cells and tissue. Oral Ampion™ significantly reduced neurological symptoms without toxicity in an in vivo model of inflammatory and immune-mediated CNS disease. Ampion™ appears to be suitable for the treatment of a variety of chronic inflammatory and immune-mediated diseases including arthritis, allergic conjunctivitis and rhinitis, inflammatory respiratory diseases and neurodegenerative CNS diseases.
« back to products page
Learn More About:
Premature Ejaculation (PE)
Premature ejaculation is a distressing male sexual dysfunction that is more common than erectile dysfunction (ED) and has a major impact on the quality of life for men and their sexual partners.
Diabetic Retinopathy
A complication of diabetes mellitus that damages the retina in the eyes and leads to blindness
Diabetic Nephropathy
A progressive complication of diabetes mellitus that leads to end-stage renal disease (ESRD) requiring kidney transplantation or chronic dialysis
| AMPE Stock Quote - delayed | ||
| Last | Change | |
| AMPE | 3.59 |  0.07 (1.91%) |
Ampio News
02/09/2012 | Press Release
Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
01/31/2012 | Press Release
01/26/2012 | News